Why the product labeling for low-dose vaginal estrogen should be changed.

Authors

JoAnn E Manson, Harvard Medical School, Boston, MA
Steven R Goldstein, New York University School of Medicine, New York, NY
Risa Kagan, University of California, San Francisco, San Francisco, CA
Andrew M Kaunitz, University of Florida College of Medicine-Jacksonville, Jacksonville, FL
James H Liu, Case Western Reserve University School of Medicine, Cleveland, OH
JoAnn V Pinkerton, University of Virginia, Charlottesville, VA
Robert W Rebar, University of Alabama - Birmingham, Birmingham, AL
Peter F Schnatz, Reading Hospital, West Reading, PA and Jefferson Medical College, Philadelphia, PA
Jan L Shifren, Harvard Medical School, Boston, MA
Cynthia A Stuenkel, University of California, San Diego San Diego, CA.
Margery L S Gass, Case Western Reserve University School of Medicine, Cleveland, OH
Wulf H Utian, Case Western Reserve University School of Medicine, Cleveland, OH

Document Type

Article

Publication Date

9-1-2014

Publication Title

Menopause (New York, N.Y.)

Volume

21

Issue

9

First Page

911

Last Page

916

Recommended Citation

Manson, J., Goldstein, S., Kagan, R., Kaunitz, A., Liu, J., Pinkerton, J., Rebar, R., Schnatz, P., Shifren, J., Stuenkel, C., Gass, M., & Utian, W. (2014). Why the product labeling for low-dose vaginal estrogen should be changed.. Menopause (New York, N.Y.), 21 (9), 911-916. https://doi.org/https://doi.org/10.1097/GME.0000000000000316